Affiliation:
1. Department of Oncology, Cancer Center Beijing Friendship Hospital Capital Medical University Beijing P. R. China
2. Department of Pharmacy Beijing Friendship Hospital Capital Medical University Beijing P. R. China
Abstract
AbstractEsophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC.
Funder
Beijing Friendship Hospital, Capital Medical University
Subject
Oncology,General Medicine